Breast Pathology and Immunohistochemistry

Immunohistochemistry is a special staining process performed on fresh or frozen breast cancer tissue removed during biopsy. IHC is used to show whether or not the cancer cells have HER2 receptors and/or hormone receptors on their surface. This information plays a critical role in treatment planning. Immunohistochemistry (IHC) is used to characterize intracellular proteins or various cell surfaces in all tissues. Individual markers, or more often panels of various marker proteins, can be used to characterize various tumor subtypes, confirm tissue of origin, distinguish metastatic from primary tumor, and provide additional information which may be important for prognosis, predicting response to therapy, or evaluating residual tumor post-treatment. There is a growing list of available antibodies, which contribute to the broader utility of immunohistochemistry for solving diagnostic problems or for determining prognosis and response to therapy in breast pathology.

  • Immunotherapy
  • Adoptive Cell Therapy
  • Adoptive Cell Therapy
  • IHC Markers
  • Adjuvant Immunotherapies

Related Conference of Breast Pathology and Immunohistochemistry

March 20-21, 2019

International Conference on Molecular Pathology

Paris | France
April 22-23, 2019

16th Annual Conference on Laboratory Medicine & Pathology

Kuala Lumpur, Malaysia
May 9-10, 2019

17th European Pathology Congress

| Amsterdam, Netherlands
June 28-29, 2019

Breast Pathology 2019

Oslo, Norway
July 29-30, 2019

17th Asia Pacific Pathology Congress

Mercure Albert Park, Melbourne, Australia
November 08 09, 2019

18th Global Congress on Pathology

San Francisco | California | United States
November 19-20, 2019

2nd European Pathology and Infectious Disease Conference

Helsinki, Finland

Breast Pathology and Immunohistochemistry Conference Speakers

Recommended Sessions

Related Journals

Are you interested in